Vincent Harijanto, Head of the Indonesian Pharmaceutical Association (GP Farmasi) business development committee, said about 95 percent of raw materials used in Indonesia's pharmaceutical industry need to be imported from abroad. This dependence on imports causes several problems, for example prices of pharmaceutical products are relatively high on the Indonesian market, while Indonesian pharmaceutical companies (and Indonesian consumers) can suddenly face rising prices in times of rupiah depreciation.

Read column ›

Over the past couple of weeks shares of Indonesia's largest bread products producer Nippon Indosari Corpindo have been recovering modestly after a severe plunge that occurred between mid-May and early July this year. On Monday (11/09) shares of the company were up 0.40 percent to IDR 1,250 a piece. So far this year, however, its shares have slid nearly 22 percent.

Read column ›

In the second half of 2017 the number of imported fruit in Indonesian supermarkets and markets has fallen rather drastically. This is mainly caused by Indonesian government regulation and performance. Firstly, the government has been eager to limit imports of tropical fruit (since 2012). Secondly, the Trade Ministry was slow in issuing import approval permits (in Indonesia: Surat Persetujuan Impor, or SPI). Hence, imports of foreign fruit tumbled.

Read column ›

One of the corporations in Indonesia that is increasingly expanding into the nation's hospital industry is Selaras Inti Corpora, also known as the Selaras Holding Group. This group, founded in 2009, is an Indonesia-based investment management and holding company with operations across the nation, particularly in land and real estate development, hospitality, and healthcare.

Read column ›